Overview

FOXO4-DRI is a synthetic peptide senolytic — a compound designed to selectively induce apoptosis in senescent cells while sparing healthy ones. It was reported in the 2017 study by Baar and colleagues in Cell as a “D-retro-inverso” peptide: the amino-acid sequence is reversed and every residue is a D-isomer, a strategy that preserves the three-dimensional pharmacophore while conferring resistance to protease degradation.

The mechanism, as reported in that primary paper, hinges on the observation that senescent cells retain nuclear p53 but sequester it through interaction with FOXO4. FOXO4-DRI is designed to disrupt the FOXO4-p53 protein-protein interaction, freeing p53 to translocate to mitochondria and initiate apoptosis in cells that have already committed to the senescence programme.

There are no published human clinical trials of FOXO4-DRI as of this writing. All published in-vivo work is in mice (primarily aged and progeroid models). Discussion in community writeups of human self-experimentation is not backed by clinical safety or efficacy data.

Mechanism (as reported in the literature)

  • Disruption of FOXO4-p53 binding. The peptide is designed to competitively bind FOXO4 at the interface that normally engages p53, freeing p53 for its pro-apoptotic role.
  • Selective apoptosis in senescent cells. In cells that are not senescent, p53 does not accumulate in the FOXO4-tethered pool and the peptide is reported not to trigger apoptosis. In senescent cells, the release of p53 is described as sufficient to commit the cell to apoptosis.
  • D-retro-inverso design. By reversing the sequence and using D-amino acids, the peptide is reported to be resistant to proteolysis while retaining a peptide-fold that mimics the native FOXO4 recognition element.
  • Broad-tissue reach in mouse work. In the Baar 2017 study, systemic administration reported effects across multiple tissues, including improved renal function and fur density in progeroid mice and improvements in a fitness measure in naturally aged mice.

Research findings

  • Baar et al., 2017 (Cell; PMID 28340339). The founding paper characterised FOXO4-DRI, demonstrated selective clearance of senescent cells in vitro and in mouse tissues, and reported functional improvements in aged and progeroid mouse models over multi-week dosing protocols. Doses in that work were on the order of 5 mg/kg by intraperitoneal injection.
  • Follow-on preclinical work. Subsequent investigators have used FOXO4-DRI as a research tool to test the “senolytic” hypothesis across models of pulmonary fibrosis, osteoarthritis, and other age-related tissue pathologies, generally with results consistent with the original characterisation but at small sample sizes.
  • Toxicology gap. No formal Phase 1 toxicology or pharmacokinetics data in humans have been published for this peptide. Body-weight-based mouse doses do not translate cleanly to human doses in the way used for small-molecule drugs, and the community translations that appear online should be understood as speculative.
  • Off-target and platform concerns. As with all senolytic strategies, questions remain in the literature about which senescent-cell populations are cleared, whether transient re-expansion occurs, and how the therapy interacts with tissues where senescent cells play a protective role (e.g., wound repair).

Common dosing (from published research protocols)

Published mouse work used approximately 5 mg/kg intraperitoneally, administered three times on alternating days per treatment cycle, with cycles separated by weeks. Community writeups discussing human self-experimentation describe protocols in the range of 5–10 mg per dose in a similar three-doses-per-cycle schedule, but these figures are not derived from any published human clinical dose-finding study. The typical_dose_range_mcg field is set at [5,000, 10,000] to reflect that community-reported envelope, and should be read as speculative rather than validated.

Reconstitution

A 5 mg vial reconstituted in 2 mL of bacteriostatic water yields a 2,500 mcg/mL solution. At community-reported dose levels this typically means most of a vial per administration, so the practical choice in research work is often either a smaller reconstitution volume (e.g., 1 mL for a 5,000 mcg/mL solution) or single-vial-per-dose preparation.

Storage

Lyophilised FOXO4-DRI is reported as stable when refrigerated. Reconstituted solutions of D-amino-acid peptides are generally reported to have longer aqueous stability than their L-amino-acid counterparts, but freezer storage is described as the standard for long-term work in this research literature.

  • Epithalon — another peptide referenced in longevity research, with a different (telomerase-oriented) mechanism.
  • SS-31 — a mitochondrial-targeted peptide often mentioned in the same longevity-research corpus.
  • NAD — a co-factor referenced in the same broader “healthspan” research literature, though not a peptide.

Common stacks

References

  • Baar, M. P., et al. (2017). “Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging.” Cell, 169(1), 132–147.e16. PMID 28340339.
  • Bourgeois, B., & Madl, T. (2018). “Regulation of cellular senescence via the FOXO4-p53 axis.” FEBS Letters, 592(12).
  • Zhang, L., et al. (2022). “Targeting cellular senescence with senotherapeutics: senolytics and senomorphics.” FEBS Journal, 289(10). (Review context for the FOXO4-DRI class.)